Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina

In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer.

They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, toxicity profiles, and what truly differentiates datopotamab deruxtecan from sacituzumab govitecan in real-world practice.

From refractory disease and disease-free interval definitions to logistics, crossover design, brain metastases, and patient-centered decision-making, this discussion offers practical insight into how clinicians should think about therapy selection, sequencing, and shared decision-making in mTNBC today.

🎧 A must-watch episode for oncologists navigating the rapidly evolving TNBC treatment landscape.